In Synergy With Interferon‐γ, Interleukin‐17 Activates Vascular Stromal Cells Toward a Proinflammatory Profile in Giant Cell Arteritis
Arthritis & Rheumatology · 2026-06 · 78 (6) · 1268-1280
DOI: 10.1002/art.70051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 23.04.2026. Verfasst von Hélène Greigert und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Clinical Immunology, Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases, Dijon University…. Hauptthemen laut MEDLINE: Interleukin-17, Giant Cell Arteritis, Interferon-gamma, Temporal Arteries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Laboratory Technician.
Abstract (Originalsprache)
Objective
This study investigated the role of interleukin‐17 (IL‐17) in giant cell arteritis (GCA), which has remained uncertain despite previous research suggesting a contribution of Th17 cells to the disease.
Methods
Temporal artery biopsies (TABs) were cultured ex vivo in MATRIGEL with IL‐17, secukinumab, or control IgG and subsequently analyzed using bulk RNA‐sequencing and real‐time quantitative polymerase chain reaction. Positive TABs with GCA features were compared to negative TABs or used to obtain in vitro cultures of myofibroblasts (MFs). Confocal microscopy analyzed IL‐17 receptor expression. MFs and peripheral blood mononuclear cells cocultures were used to study T cell polarization.
Results
Transcriptomic analysis showed that secukinumab treatment of positive TABs reduced expression of genes linked to vascular inflammation, notably IL6 . Real‐time quantitative polymerase chain reaction analysis confirmed that secukinumab decreased messenger RNA encoding IL‐6, CCL20, and granulocyte macrophage colony‐stimulating factor (GM‐CSF) in positive TABs, whereas IL‐17 up‐regulated them in negative TABs. No changes were observed regarding the expression of genes related to vascular remodeling. IL‐17 receptor chains were expressed on MFs, and their expression was enhanced by interferon‐γ (IFN‐γ). Real‐time quantitative polymerase chain reaction and Luminex analyses confirmed IL‐17–driven upregulation of IL‐6, CCL20, CCL2, GM‐CSF, and vascular endothelial growth factor (VEGF) in MFs, which was reversed by secukinumab. Addition of IFN‐γ to the culture increased the expression level of IL‐17 receptor chains, resulting in a synergistic effect. Additionally, IL‐17–pretreated MFs promoted Th17 polarization.
Conclusion
IL‐17 exacerbates vascular inflammation in GCA by activating MFs and synergizing with IFN‐γ to increase production of proinflammatory cytokines (IL‐6, GM‐CSF), chemokines (CCL20, CCL2), and angiogenic factors (VEGF), indicating that IL‐17 is a key contributor to disease pathogenesis. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Clinical Immunology, Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases, Dijon University Hospital, Université EPE Bourgogne Europe, Dijon, France.
- Department of Vascular Medicine, Dijon University Hospital, Université EPE Bourgogne Europe, Dijon, France.
- Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France.
- Department of Rheumatology, Dijon University Hospital, Université EPE Bourgogne Europe, Dijon, France.
- Unit of Molecular Biology, Department of Biology and Pathology of Tumors, Georges-François Leclerc Cancer Center, Unicancer, ICMUB UMR CNRS 6302, Dijon, France.
- Department of Ophthalmology, Dijon University Hospital, Université EPE Bourgogne Europe, Dijon, France.
ORCID-Profile: André Ramon
Förderung
- Laboratory Technician
Zitieren
APA
Greigert, H., Ramon, A., Cladiere, C., Lamarthée, B., Richard, C., Ciudad, M., Varin, A., Herrmann, N., Praliaud, R., Brenac, G., Razanamahery, J., Arnould, L., Gabrielle, P. H., Creuzot-Garcher, C., Tarris, G., Martin, L., Audia, S., Boidot, R., Bonnotte, B., & Samson, M. (2026). In Synergy With Interferon‐γ, Interleukin‐17 Activates Vascular Stromal Cells Toward a Proinflammatory Profile in Giant Cell Arteritis. Arthritis & Rheumatology, 78(6), 1268-1280. https://doi.org/10.1002/art.70051
Vancouver
Greigert H, Ramon A, Cladiere C, Lamarthée B, Richard C, Ciudad M, et al. In Synergy With Interferon‐γ, Interleukin‐17 Activates Vascular Stromal Cells Toward a Proinflammatory Profile in Giant Cell Arteritis. Arthritis & Rheumatology. 2026;78(6):1268-1280. doi:10.1002/art.70051
BibTeX
@article{Greigert2026,
author = {Greigert, Hélène and Ramon, André and Cladiere, Claudie and Lamarthée, Baptiste and Richard, Corentin and Ciudad, Marion and Varin, Alexis and Herrmann, Noémie and Praliaud, Roman and Brenac, Guillaume and Razanamahery, Jérôme and Arnould, Louis and Gabrielle, Pierre-Henry and Creuzot-Garcher, Catherine and Tarris, Georges and Martin, Laurent and Audia, Sylvain and Boidot, Romain and Bonnotte, Bernard and Samson, Maxime},
title = {In Synergy With Interferon‐γ, Interleukin‐17 Activates Vascular Stromal Cells Toward a Proinflammatory Profile in Giant Cell Arteritis},
journal = {Arthritis & Rheumatology},
year = {2026},
volume = {78},
number = {6},
pages = {1268--1280},
doi = {10.1002/art.70051}
}
EUVIMED